Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
ImpactMinor 15/100
Why it mattersRule-based estimate: event keywords (+6), soft/evergreen signals; trust 7/10.
RegionsGlobal
Published2 h ago (Fri, 02 Oct 2026 12:31:46 GMT)
RetrievedFri, 02 Oct 2026 14:00:27 GMT via rss
ClassifiedFri, 02 Oct 2026 14:00:31 GMT by heuristic